Eczacıbaşı Group, Founder of Turkey first modern pharmaceutical factory, announced Wednesday that he had reached an agreement purchase 99.96% share in Gensenta, owned by leading American pharmaceutical company Amgen, for 135 million dollars.
The purchase of Gensenta will be completed once it is approved by the Turkish Competition Authority.
Bülent Eczacıbaşı, President of The board of Eczacıbaşı Holding said that the acquisition of Gensenta represents an important investment in field of health care.
“As a company that aspires to be a leader of Modern, high-quality and healthy life, we will expand our health care activities both in Turkey and international markets with Innovative products and a wide product range in different treatment areas.
Ekzajibashi stressed that the acquisition is fueling growth By adding local production capabilities in Pharmaceuticals and biosimilar products and active components of our investment portfolio as well as export efficiency.”
Amgen stated that it will continue its activities in Turkey continues to serve patients after strategic sales of Genecenta.
Gensenta is among the most established companies in Turkey in Pharmaceutical industry. The company that started its operations as a factory in 1923 and broke new a land in Sector in the name of Mustafa Nefzat Pharmaceuticals since 1957, purchased by Amgen in 2012. Name of The company was then changed to Jinsinta in 2020.
According to the statement made by the company; Gensenta, which is issued to various countriesbecame the export champion in sector twice in The past Years. Gensenta, which gained about 47% of revenue of the end of 2021, is among the most important producers and exporters of freeze-dried vials in Turkey and region. penicillin groupEtodolac and others active Pharmaceutical ingredients are produced in raw Gensenta material production facilities.
